[Objectives] To make a systematic evaluation of the clinical efficacy and safety of Shenqi Fuzheng Injection in the treatment of colorectal cancer. [Methods] Databases,such as China National Knowledge Infrastructure( ...[Objectives] To make a systematic evaluation of the clinical efficacy and safety of Shenqi Fuzheng Injection in the treatment of colorectal cancer. [Methods] Databases,such as China National Knowledge Infrastructure( CNKI),Wanfang,China biomedical literature service system( CBM),CQVIP,Medline,and Cochrane,were searched for the time before April 2017. The randomized controlled trial( RCT) that met the inclusion criteria was screened. Then,quality evaluation was made based on the modified Jadad scale. Data were extracted and meta-analysis was made with the aid of Review Manager 5. 3. [Results] Finally,21 papers met the inclusion criteria,including 2 high quality papers. The average Jadad score was 2. 5 points,1 589 patients were included. Meta-analysis results showed that the intervention of the experimental group could improve the quality of life[OR = 3. 32,95% CI( 2. 33,4. 74),P < 0. 000 01]; improve the short-term efficacy[OR =1. 68,95% CI( 1. 26,2. 24),P =0. 000 4]; reduce the incidence of adverse chemotherapy reactions such as reducing the gastrointestinal reactions[OR = 0. 33,95% CI( 0. 25,0. 43),P < 0. 000 01],reducing myelosuppressive reactions[OR = 0. 33,95% CI( 0. 24,0. 46),P < 0. 000 01]; improve the immune functions,such as increasing CD4/CD8 cell ratio[WMD = 1. 19,95% CI( 0. 24,0. 41),( P <0. 000 01) ],and increasing the number of NK cells[WMD =1. 72,95% CI( 5. 62,14. 30),( P <0. 000 01) ]. [Conclusions]The clinical effect of Shenqi Fuzheng Injection in the treatment of colorectal cancer is better than that of chemotherapy alone,but it needs more highquality RCTs to improve the level of research.展开更多
基金Supported by Science and Technology Planning Project of Shenzhen(JCYJ20150401163247231)
文摘[Objectives] To make a systematic evaluation of the clinical efficacy and safety of Shenqi Fuzheng Injection in the treatment of colorectal cancer. [Methods] Databases,such as China National Knowledge Infrastructure( CNKI),Wanfang,China biomedical literature service system( CBM),CQVIP,Medline,and Cochrane,were searched for the time before April 2017. The randomized controlled trial( RCT) that met the inclusion criteria was screened. Then,quality evaluation was made based on the modified Jadad scale. Data were extracted and meta-analysis was made with the aid of Review Manager 5. 3. [Results] Finally,21 papers met the inclusion criteria,including 2 high quality papers. The average Jadad score was 2. 5 points,1 589 patients were included. Meta-analysis results showed that the intervention of the experimental group could improve the quality of life[OR = 3. 32,95% CI( 2. 33,4. 74),P < 0. 000 01]; improve the short-term efficacy[OR =1. 68,95% CI( 1. 26,2. 24),P =0. 000 4]; reduce the incidence of adverse chemotherapy reactions such as reducing the gastrointestinal reactions[OR = 0. 33,95% CI( 0. 25,0. 43),P < 0. 000 01],reducing myelosuppressive reactions[OR = 0. 33,95% CI( 0. 24,0. 46),P < 0. 000 01]; improve the immune functions,such as increasing CD4/CD8 cell ratio[WMD = 1. 19,95% CI( 0. 24,0. 41),( P <0. 000 01) ],and increasing the number of NK cells[WMD =1. 72,95% CI( 5. 62,14. 30),( P <0. 000 01) ]. [Conclusions]The clinical effect of Shenqi Fuzheng Injection in the treatment of colorectal cancer is better than that of chemotherapy alone,but it needs more highquality RCTs to improve the level of research.
